Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours
This is a prospective, open-label, multicenter phase IV.II study. Patients with local relapse breast cancer will receive radiotherapy concomitant to the administration of capecitabine.
Breast Cancer
DRUG: Capecitabine|RADIATION: Radiotherapy
Complete clinical response rate, The disease evaluation will be measured by RECIST criteria in the 28 days after the end of the radiotherapy by Magnetic resonance imaging (MRI)., 28 days after the end of the radiotherapy
Evaluation of the concomitant administration of capecitabine and radiotherapy as the first treatment, Safety will be assessed by standard clinical and laboratory tests. Adverse events grade will be defined by the National Cancer Institute Common Terminology Criteria for Adverse (NCI-CTCAE)., 28 days after the end of the radiotherapy
Total dose of radiotherapy will be 50 Gy administered in daily session of 200 centigray (cGy). Radiotherapy treatment will not be longer than 6 weeks.

All patients will receive 1650 mg/m2 by mouth, per day (825 mg/m2 twice a day (p.o. bid) for 35 days.

Tissue samples must be analysed to determinate the human epidermal growth factor receptor-2 (HER2) by fluorescent in situ hybridization (FISH) technical.